Publications and Project Outcomes
This section highlights key publications, findings, and insights from the PICKED project, showcasing our contributions to chronic kidney disease (CKD) research and personalized medicine. Our work focuses on advancing biomarkers for early detection, developing models for disease progression, and exploring innovative intervention strategies to improve patient outcomes.
Our multidisciplinary team regularly publishes in high-impact journals and presents at international conferences, ensuring that our findings contribute to the broader scientific community. Stay tuned for the latest research updates and discoveries from the PICKED project!
Computational Drug Repositioning in Cardiorenal Disease: Advancing Therapeutic Innovation
Drug repositioning—the search for new therapeutic uses of existing drugs—has gained increasing momentum, particularly in tackling complex conditions like cardiorenal disease. While publications in this field continue to rise, the true measure of success lies in translating computational discoveries into real-world patient benefits.
We explore cutting-edge approaches in computational drug repositioning, leveraging bioinformatics, omics data integration, and network-based modeling to identify novel therapeutic opportunities. Despite significant progress, challenges remain in moving promising candidates from discovery to clinical application. Addressing these barriers with targeted strategies will be key to ensuring that repositioned drugs reach patients in need.
🔗 Read the full article here: DOI: 10.1002/pmic.202400109
This research is supported by the PICKED project (HORIZON-MSCA-2023-DN-01, 101168626) and other major European initiatives, driving forward the future of precision medicine.
Overview on drug repositioning approaches.
Clinical Proteomics: From Scientific Breakthroughs to Patient Benefit
This article examines the progress and challenges of clinical proteomics, a field that has produced over 40,000 publications but has yet to make a widespread impact in clinical practice. Success should not be measured by publication volume alone but by tangible improvements in patient management and treatment.
We outline concrete solutions, emphasizing the need for a patient-centric approach to ensure that research efforts remain aligned with clinical utility. By addressing these barriers, we aim to shape the future of clinical proteomics, driving meaningful improvements in healthcare.
🔗 Read the full article here: DOI: 10.1002/pmic.202400346
This study represents a significant contribution to the field, supported by the PICKED project (HORIZON-MSCA-2023-DN-01, 101168626) and other major European research initiatives, driving innovation in personalized medicine.
Biological functions of a hypothetical protein, Pac1, of which differently modified variants with different biological functions exist. The (hypothetical) protein Pac1 has little biological activity as a native polypeptide chain, but is converted into its active form, Pac1A1, by phosphorylation (red) and glycosylation (blue). The protein can also be specifically cleaved by proteases into Pac1A, which fulfils an alternative biological function, Pac1B which has no known function, and Pac2A and B, which inhibit the activity of Pac1A1.
Exploring the Role of GLP-1 RAs in CKD and Cardiometabolic Health
This article explores the potential of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) as transformative agents in the management of chronic kidney disease (CKD), type 2 diabetes (T2DM), obesity, and cardiovascular disease (CVD). These medications, including liraglutide, semaglutide, and tirzepatide, have shown significant benefits in metabolic control, weight reduction, and cardiovascular protection, making them an important consideration for nephrologists.
🔗 Read the full article here: https://pubmed.ncbi.nlm.nih.gov/39583142/
This marks an exciting milestone for the PICKED project, contributing valuable insights to the intersection of nephrology, metabolic health, and personalized medicine.
Obesity is an independent risk factor for CKD with a complex pathophysiology involving shared risk factors, direct effects of obesity and indirect effects through promotion of vascular disease, hypertension and T2DM. Indirect effects through BP and hyperglycaemia are estimated to mediate up to 83% of the negative impact of obesity on CKD. Mediation analyses of liraglutide and semaglutide in the T2DM CVOTs estimated up 48% mediation of kidney effects indirectly, through BP and hyperglycaemia. Similar analyses are awaited for overweight/obesity trials in which participants did not have T2DM.
©Copyright. All rights reserved.
Wir benötigen Ihre Zustimmung zum Laden der Übersetzungen
Wir nutzen einen Drittanbieter-Service, um den Inhalt der Website zu übersetzen, der möglicherweise Daten über Ihre Aktivitäten sammelt. Bitte überprüfen Sie die Details in der Datenschutzerklärung und akzeptieren Sie den Dienst, um die Übersetzungen zu sehen.